HIGHLIGHTS
- who: A type I IFN and collaborators from the Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, TJ, UK have published the paper: A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS [version 2;, in the Journal: (JOURNAL) of 20/05/2021
- what: The authors report using LIMMA analysis of NDN proteomes a type I IFN signature within the COVID-19 ARDS neutrophils . Whilst total cell counts are retained in patients receiving dexamethasone therapy, the authors report an associated contraction of immature LDN neutrophil populations . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.